Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 30, 2017

Primary Completion Date

July 11, 2018

Study Completion Date

February 15, 2019

Conditions
Depression
Interventions
DRUG

Ammoxetine Hydrochloride Enteric-coated Tablets

There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.

DRUG

placebo enteric-coated tablets

There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.

Trial Locations (1)

610000

Sichuan huaxi hospital 1 ward., Chengdu

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT03456388 - Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter